REJOICE-PanTumor01: A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants with Advanced/Metastatic Solid Tumors

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513307-13-00

Acronym

DS6000-126

Enrollment

Registered

2025-03-24

Start date

2025-05-26

Completion date

Unknown

Last updated

2026-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced/metastatic solid tumors including gynecological cancers (endometrial cancer, cervical cancer, and nonhigh- grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and ccRCC)

Brief summary

For all cohorts except ccRCC: ORR is defined as the proportion of participants with a BOR of confirmed CR or confirmed PR according to RECIST version 1.1 criteria.For ccRCC cohort only: DCR is defined as the proportion of participants who achieved a BOR of confirmed CR, confirmed PR, or stable disease (maintained for ≥5 weeks) according to RECIST version 1.1. Incidence of TEAEs, SAEs, AESIs

Interventions

DRUGRaludotatug Deruxtecan

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
For all cohorts except ccRCC: ORR is defined as the proportion of participants with a BOR of confirmed CR or confirmed PR according to RECIST version 1.1 criteria.For ccRCC cohort only: DCR is defined as the proportion of participants who achieved a BOR of confirmed CR, confirmed PR, or stable disease (maintained for ≥5 weeks) according to RECIST version 1.1. Incidence of TEAEs, SAEs, AESIs	—

Countries

Belgium, Denmark, France, Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026